Status:

WITHDRAWN

Ventricular Sling for Heart Failure With Reduced Ejection Fraction

Lead Sponsor:

University of Miami

Conditions:

Heart Failure

Cardiomyopathy, Dilated

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this research is to investigate the effect of using this surgical technique in conjunction with bypass surgery to improve heart function and size, as well as decrease the possibility of...

Detailed Description

The Sling is used to draw together the ventricular walls at the base of the papillary muscles. This technique has previously been used in conjunction with mitral valve surgery, and has shown significa...

Eligibility Criteria

Inclusion

  • Patients with symptomatic heart failure with reduced ejection fraction and either ischemic or non-ischemic cardiomyopathies, referred for CABG surgery. Suitability for the ventricular sling procedure is determined by the surgeon and or cardiologist, using some or all the criteria described below:
  • Left ventricular end diastolic diameter is greater than or equal to 55mm.
  • Ejection fraction ≥20% and ≤40%
  • FMR grade ≤ 2+ (≤ mild FMR) as defined by the guidelines of the American society of echocardiography at the time of the study approval (via a transthoracic or transesophageal echo).
  • End-systolic Interpapillary muscle distance ≥ 20mm
  • Cardiomyopathy of ischemic or non-ischemic origins.
  • Able to sign informed consent and release of medical information forms, or able to assign a legal representative who can sign on the patient's behalf.

Exclusion

  • Any evidence of structural (chordal or leaflet) mitral lesions.
  • Planned concomitant intra-operative procedures (except for closure of patent foramen ovale or atrial septal defect or coronary revascularization)
  • Planned concomitant intra-operative Maze procedure for symptomatic paroxysmal atrial fibrillation.
  • Persistent atrial fibrillation
  • Prior mitral valve repair
  • Contraindication for cardiopulmonary bypass
  • Clinical signs of cardiogenic shock
  • ST segment elevation myocardial infarction within 14 days prior to inclusion in this study.
  • Congenital heart disease (except PFO or ASD)
  • Chronic renal insufficiency defined by Creatinine ≥ 3.0 or chronic renal replacement therapy, who are contraindicated for cardiac surgery
  • Recent history of psychiatric disease that is likely to impair compliance with the study protocol, in the judgement of the investigator
  • Pregnancy

Key Trial Info

Start Date :

December 12 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2027

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04475315

Start Date

December 12 2021

End Date

December 1 2027

Last Update

May 11 2022

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.